Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/05/05 23:26:33」(JST)

wiki en

Voglibose (INN and USAN, trade name Voglib, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. Voglibose delays the absorption of glucose thereby reducing the risk of macrovascular complications. Voglibose is a research product of Takeda Pharma, a Japan-based company.

Postprandial hyperglycemia (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal.

There are three drugs which belong to this class, acarbose, miglitol and voglibose, of which voglibose is the newest. Voglibose has fewer side effects than both acarbose and miglitol. But acarbose has an edge over voglibose in terms of efficacy (FPG, PPHG, HBA_1c).

There are several trials supporting the use of voglibose in the management of PPHG. Also, it has been established that it is PPHG, not FPG, which is the marker of cardiovascular disorders associated with diabetes. So, controlling PPHG is imperative and voglibose is indicated for the management of PPHG.

External links

Ranbaxy announcement (Bad link)

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 糖尿病の治療におけるα-グルコシダーゼ阻害剤およびリパーゼ阻害剤 alpha glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus
2. 2型糖尿病の予測及び予防 prediction and prevention of type 2 diabetes mellitus
3. 糖尿病の治療における低血糖のマネージメント management of hypoglycemia during treatment of diabetes mellitus

English Journal

Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes.

Imamura A, Kusunoki M, Ueda S, Hayashi N, Imai Y.SourceMoriya Keiyu Hospital, 980-1, Tatuzawa, Moriya City, Ibaraki, 302-0118, Japan, imamura.akira@keiyu.or.jp.
Diabetes therapy : research, treatment and education of diabetes and related disorders.Diabetes Ther.2013 Jan 10. [Epub ahead of print]
INTRODUCTION: Dapagliflozin is an orally administered selective sodium-glucose cotransporter 2 (SGLT2) inhibitor under development for the treatment of type 2 diabetes mellitus (T2DM). Dapagliflozin lowers blood glucose through a reduction in renal glucose reabsorption. This study was performed to a
PMID 23307267

Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes.

Araki E, Kawamori R, Inagaki N, Watada H, Hayashi N, Horie Y, Sarashina A, Thiemann S, von Eynatten M, Dugi K, Woerle HJ.SourceDepartment of Metabolic Medicine, Kumamoto University Graduate School of Medicine, Kumamoto, Japan.
Diabetes, obesity & metabolism.Diabetes Obes Metab.2012 Nov 19. doi: 10.1111/dom.12039. [Epub ahead of print]
AIMS: In a phase III study conducted among Japanese patients with type 2 diabetes mellitus (T2DM), linagliptin 5 and 10 mg showed clinically meaningful improvements in glycaemic parameters after 12 and 26 weeks compared with placebo and voglibose, respectively. This extension study assessed long
PMID 23163910

Japanese Journal

糖尿病血液透析患者におけるアログリプチンの有効性と安全性の検討

藤井由季,阿部雅紀,樋口輝美,鈴木紘子,松本史郎,水野真理,菊池史,岡田一義,相馬正義
日本透析医学会雑誌 46(7), 633-640, 2013
糖尿病血液透析患者におけるDPP-4阻害薬アログリプチンの有効性と安全性について検討した．HbA1c（NGSP）値＞6.9％またはグリコアルブミン（GA）値＞20.0％で，食事・運動療法またはDPP-4阻害薬以外の経口血糖降下薬にて治療中の2型糖尿病血液透析患者28例（男性22例，女性6例，平均年齢69.9±9.5歳，平均透析歴55.0±51.0か月）を対象とした．インスリン治療中の患者は除外した …
NAID 130003372793

低分子生体成分ミミック体の創出を基盤とする創薬化学研究

高畑廣紀
YAKUGAKU ZASSHI 133(5), 575-585, 2013
… Some of the prepared L-forms showed potent inhibitory activities towards intestinal maltase, with IC50 values comparable to those of commercial drugs such as acarbose, voglibose, and miglitol, which are used in the treatment of type 2 diabetes. …
NAID 130003361951

Effects of Voglibose and Nateglinide on Glycemic Status and Coronary Atherosclerosis in Early-Stage Diabetic Patients

KATAOKA Yu,YASUDA Satoshi,MIYAMOTO Yoshihiro,SASE Kazuhiro,KOSUGE Masami,KIMURA Kazuo,YOSHIMASA Yasunao,MIYAZAKI Shunichi
Circulation journal : official journal of the Japanese Circulation Society 76(3), 712-720, 2012-02-25
… The 302 patients with coronary artery disease (CAD), impaired glucose tolerance/diabetes mellitus (DM) pattern according to 75-g oral glucose tolerance test and HbA1c <6.9% were randomly assigned to life-style intervention (n=101), voglibose (0.9mg/day, n=100) or nateglinide treatment (180mg/day, n=101). … Although voglibose significantly increased the number of patients with normal glucose tolerance at 1 year, there were no significant differences in coronary atherosclerotic changes at 1 year. …
NAID 10030130334

Related Pictures

★リンクテーブル★

リンク元	「αグルコシダーゼ阻害薬」「ボグリボース」

「αグルコシダーゼ阻害薬」

Voglibose
Systematic (IUPAC) name
	(1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol
Clinical data
AHFS/Drugs.com	International Drug Names
Identifiers
CAS Registry Number	83480-29-9
ATC code	A10BF03
PubChem	CID 444020
DrugBank	DB04878
ChemSpider	392046
UNII	S77P977AG8
KEGG	D01665
ChEMBL	CHEMBL476960
Chemical data
Formula	C10H21NO7
Molecular mass	267.28 g/mol
	SMILES OC[C@@]1(O)C[C@H](NC(CO)CO)[C@H](O)[C@@H](O)[C@@H]1O;
	InChI InChI=1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1 ; Key:FZNCGRZWXLXZSZ-CIQUZCHMSA-N ;
(what is this?) (verify)